Ann: First phase 1B trial of NK cells with IL-2 & Vactosertib, page-21

Don't worry, with so many cutting edge trials and later results to come the sp will adjust accordingly. I waited 5 years to see IMU taking off.

CHM is benefitting from IMU's learning curve and has already more under its hat than IMU had after 4 years. Pre-clinical drugs / techs are bought out in the US for at least USD 500m, about AUD 700m, and CHM got 3 with an above average chance to succeed.

Sp got hammered due to macros, sell first, ask later. At some stage we will see the opposite, buy first, ask later.

Could take a while for that reversal but any positive market response to IMU's Her-Vaxx OS data release, due at any day, could put CHM into IMU's slip stream because of the " Hopper has done it again " - effect.

JC and LC, almost identical scientists / CEOs - PH not just a genius in selecting hottest techs, expert in hiring top staff as well.

GLTA